Chapin Davis’s GSK GSK Stock Holding History

Chapin Davis’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,988	Closed	-$441K	–	268
2026 Q1	$441K	Sell	7,988 -357	-4%	-$19.3K	0.1%	168
2025 Q4	$409K	Sell	8,345 -116	-1%	-$5.41K	0.1%	163
2025 Q3	$365K	Sell	8,461 -1,416	-14%	-$55.3K	0.09%	172
2025 Q2	$379K	Sell	9,877 -533	-5%	-$20.4K	0.1%	162
2025 Q1	$403K	Sell	10,410 -4,088	-28%	-$150K	0.14%	140
2024 Q4	$593K	Hold	14,498	–	–	0.19%	115
2024 Q3	$593K	Sell	14,498 -93	-0.6%	-$3.81K	0.19%	116
2024 Q2	$562K	Buy	14,591 +360	+3%	+$15.1K	0.19%	119
2024 Q1	$610K	Buy	14,231 +300	+2%	+$12.4K	0.22%	105
2023 Q4	$516K	Hold	13,931	–	–	0.22%	115
2023 Q3	$505K	Sell	13,931 -2,610	-16%	-$92.6K	0.24%	103
2023 Q2	$590K	Sell	16,541 -168	-1%	-$6.03K	0.28%	96
2023 Q1	$594K	Sell	16,709 -330	-2%	-$11.5K	0.31%	92
2022 Q4	$599K	Buy	+17,039	New	+$568K	0.35%	84

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Chapin Davis's GSK Position: Q2 2026 in Review

Chapin Davis sold out of GSK (GSK) in Q2 2026, closing a stake of 7,988 shares — an estimated $441K sold.

Chapin Davis first reported a position in GSK in Q4 2022 and held it in 14 quarters. The position peaked at $610K in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Chapin Davis reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Chapin Davis sold 7,988 GSK shares in Q2 2026, an estimated $441K.
Chapin Davis first reported a position in GSK in Q4 2022 and held it in 14 quarters.
Chapin Davis's GSK position peaked at $610K in Q1 2024.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.